Another standard therapy for advanced NSCLC is immune checkpoint blockade with programmed cell death protein 1 (PD-1) and programmed cell death ligand (PD-L1) inhibitors [91,92]. Here, PDCD1 is linked to non-small cell lung carcinoma.